

Table SI. Univariate and multivariate Cox proportional hazard analyses of progression-free survival.

Factors	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age, years		0.469		
≤65	1.000			
>65	1.171 (0.764-1.795)			
Sex		0.554		
Male	1.000			
Female	0.855 (0.509-1.435)			
Histological type		0.217		
Adenocarcinoma	1.000			
Non-adenocarcinoma	1.304 (0.855-1.990)			
Smoking status		0.269		
Never smoker	1.000			
Current/former smoker	1.257 (0.838-1.884)			
ECOG PS		0.038		0.015
0-1	1.000		1.000	
2	1.738 (1.032-2.926)		1.953 (1.140-3.347)	
Brain metastases		0.409		
No	1.000			
Yes	0.827 (0.526-1.299)			
Bone metastases		0.525		
No	1.000			
Yes	1.145 (0.755-1.737)			
Liver metastases		0.161		
No	1.000			
Yes	1.426 (0.868-2.343)			
First-line response		0.036		0.015
PD + SD	1.000		1.000	
CR + PR	0.632 (0.413-0.969)		0.579 (0.373-0.901)	
Second-line treatment		0.013		0.022
Non-IBP	1.000		1	
IBP	0.590 (0.388-0.896)		0.613 (0.403-0.933)	

ECOG PS, Eastern Cooperative Oncology Group performance status; IBP, immunotherapy beyond progression; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; HR, hazard ratio; CI, confidence interval.

Table SII. Univariate and multivariate Cox proportional hazard analyses of overall survival.

Factors	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age, years		0.159		
≤65	1.000			
>65	1.473 (0.860-2.525)			
Sex		0.188		
Male	1.000			
Female	0.587 (0.266-1.298)			
Histological type		0.005		0.002
Adenocarcinoma	1.000		1.000	
Non-adenocarcinoma	2.099 (1.244-3.543)		2.339 (1.380-3.964)	
Smoking status		0.270		
Never smoker	1.000			
Current/former smoker	1.349 (0.793-2.294)			
ECOG PS		<0.001		<0.001
0-1	1.000		1.000	
2	2.849 (1.607-5.051)		2.897 (1.616-5.194)	
Brain metastases		0.944		
No	1.000			
Yes	1.020 (0.582-1.790)			
Bone metastases		0.651		
No	1.000			
Yes	1.129 (0.668-1.908)			
Liver metastases		0.056		
No	1.000			
Yes	1.844 (0.985-3.452)			
First-line response		0.237		
PD + SD	1.000			
CR + PR	0.722 (0.420-1.239)			
Second-line treatment		0.044		0.072
Non-IBP	1.000		1.000	
IBP	0.583 (0.345-0.984)		0.613 (0.360-1.045)	

ECOG PS, Eastern Cooperative Oncology Group performance status; IBP, immunotherapy beyond progression; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; HR, hazard ratio; CI, confidence interval.